

Sample MOLLY - G - WATERMELON

Delta9 THC	ND	THCa	ND	Total THC (THCa * 0.877 + THC)	ND	Delta8 THC	<LOQ
------------	----	------	----	--------------------------------	----	------------	------



Sample ID SD251029-108 (126406)

Matrix Edible

Tested for MOLLY

Sampled - Received Oct 29, 2025

Reported Nov 04, 2025

Analyses executed CANX, 4AD, TRY, PSY

Unit Mass (g) 12.007

Num. of Servings 3

Serving Size (g) 4.0

CANx - Cannabinoids

Analyzed Oct 30, 2025 | Instrument HPLC-VWD | Method SOP-001

The expanded Uncertainty of the Cannabinoids analysis is approximately $\pm 7.81\%$ at the 95% Confidence Level

Analyte	LOD mg/g	LOQ mg/g	Result %	Result mg/g	Result mg/Serving	Result mg/Unit
11-Hydroxy- $\Delta 8$ -Tetrahydrocannabivarin (11-Hyd- $\Delta 8$ -THCV)	0.013	0.041	ND	ND	ND	ND
Cannabidiol (CBD)	0.006	0.02	ND	ND	ND	ND
Abnormal Cannabidiol (a-CBDO)	0.013	0.038	ND	ND	ND	ND
(+/-)-9B-hydroxy-Hexahydrocannabinol (9b-HHC)	0.015	0.045	ND	ND	ND	ND
11-Hydroxy- $\Delta 8$ -Tetrahydrocannabinol (11-Hyd- $\Delta 8$ -THC)	0.015	0.045	ND	ND	ND	ND
Cannabidiolic Acid (CBDA)	0.033	0.16	ND	ND	ND	ND
Cannabigerol Acid (CBGA)	0.033	0.16	ND	ND	ND	ND
Cannabigerol (CBG)	0.048	0.16	ND	ND	ND	ND
Cannabidiol (CBD)	0.069	0.229	<LOQ	<LOQ	<LOQ	<LOQ
1(S)-Tetrahydrocannabinol (1(S)-H4-CBD)	0.008	0.026	ND	ND	ND	ND
1(R)-Tetrahydrocannabinol (1(R)-H4-CBD)	0.016	0.049	ND	ND	ND	ND
Tetrahydrocannabivarin (THCV)	0.049	0.162	ND	ND	ND	ND
$\Delta 8$ -tetrahydrocannabivarin ($\Delta 8$ -THCV)	0.012	0.036	ND	ND	ND	ND
Cannabidiolhexol (CBDH)	0.014	0.042	ND	ND	ND	ND
Tetrahydrocannabutol ($\Delta 9$ -THCB)	0.01	0.029	ND	ND	ND	ND
Cannabinol (CBN)	0.047	0.16	<LOQ	<LOQ	<LOQ	<LOQ
Cannabidiphorol (CBDP)	0.016	0.049	ND	ND	ND	ND
exo-THC (exo-THC)	0.016	0.8	ND	ND	ND	ND
Tetrahydrocannabinol ($\Delta 9$ -THC)	0.092	0.307	ND	ND	ND	ND
$\Delta 8$ -tetrahydrocannabinol ($\Delta 8$ -THC)	0.044	0.16	<LOQ	<LOQ	<LOQ	<LOQ
(6aR,9S)- $\Delta 10$ -Tetrahydrocannabinol ((6aR,9S)- $\Delta 10$)	0.015	0.8	ND	ND	ND	ND
Hexahydrocannabinol (S Isomer) (9s-HHC)	0.017	0.8	ND	ND	ND	ND
(6aR,9R)- $\Delta 10$ -Tetrahydrocannabinol ((6aR,9R)- $\Delta 10$)	0.007	0.8	ND	ND	ND	ND
Hexahydrocannabinol (R Isomer) (9r-HHC)	0.016	0.8	ND	ND	ND	ND
Tetrahydrocannabinolic Acid (THCA)	0.117	0.389	ND	ND	ND	ND
$\Delta 9$ -Tetrahydrocannabihexol ($\Delta 9$ -THCH)	0.02	0.061	ND	ND	ND	ND
Cannabinol Acetate (CBNO)	0.009	0.027	ND	ND	ND	ND
9(S)-Hexahydrocannabinolic Acid (9(S)-HHCA)	0.063	0.065	ND	ND	ND	ND
9(R)-Hexahydrocannabinolic Acid (9(R)-HHCA)	0.191	0.196	ND	ND	ND	ND
$\Delta 9$ -Tetrahydrocannabiphorol ($\Delta 9$ -THCP)	0.017	0.8	ND	ND	ND	ND
$\Delta 8$ -Tetrahydrocannabiphorol ($\Delta 8$ -THCP)	0.041	0.8	ND	ND	ND	ND
Cannabicitran (CBT)	0.005	0.16	ND	ND	ND	ND
$\Delta 8$ -THC-O-acetate ($\Delta 8$ -THCO)	0.076	0.8	ND	ND	ND	ND
9(S)-HHCP (s-HHCP)	0.013	0.041	ND	ND	ND	ND
$\Delta 9$ -THC-O-acetate ($\Delta 9$ -THCO)	0.066	0.8	ND	ND	ND	ND
9(R)-HHCP (r-HHCP)	0.015	0.045	ND	ND	ND	ND
9(S)-HHC-O-acetate (s-HHCO)	0.037	0.112	ND	ND	ND	ND
9(R)-HHC-O-acetate (r-HHCO)	0.031	0.093	ND	ND	ND	ND
3-octyl- $\Delta 8$ -Tetrahydrocannabinol ($\Delta 8$ -THC-C8)	0.021	0.062	ND	ND	ND	ND
Total THC (THCa * 0.877 + $\Delta 9$ THC)			ND	ND	ND	ND
Total THC + $\Delta 8$ THC + $\Delta 10$ THC (THCa * 0.877 + $\Delta 9$ THC + $\Delta 8$ THC + $\Delta 10$ THC)			ND	ND	ND	ND
Total CBD (CBDo * 0.877 + CBD)			ND	ND	ND	ND
Total CBG (CBGa * 0.877 + CBG)			ND	ND	ND	ND
Total HHC (9r-HHC + 9s-HHC)			ND	ND	ND	ND
Total Cannabinoids Analyzed			ND	ND	ND	ND

4AD - 4AD Tryptamines

Analyzed Oct 30, 2025 | Instrument HPLC VWD | Method SOP-4AD

The expanded Uncertainty of the 4AD Tryptamines analysis is approximately $\pm 7.81\%$ at the 95% Confidence Level

Analyte	LOD ppm	LOQ ppm	Result %	Result mg/g	Result mg/Serving	Result mg/Unit
Mescaline (MESC)	0.19	0.584	ND	ND	ND	ND
N-methyl Tryptamine (NMT)	0.004	0.013	ND	ND	ND	ND
4-Hydroxy-MET (4-HO-MET)	0.013	0.04	ND	ND	ND	ND
n,n Dimethyltryptamine (DMT)	0.015	0.048	ND	ND	ND	ND
Psilocetin (PSLA)	0.015	0.044	ND	ND	ND	ND
4-Hydroxy-DET (4-HO-DET)	0.014	0.042	ND	ND	ND	ND

4-Acetoxy-MET (4-AcO-MET)	0.018	0.053	ND	ND	ND	ND
4-Acetoxy-DET (4-AcO-DET)	0.004	0.011	ND	ND	ND	ND
4-Bromo-DMP (2C-B)	0.19	0.576	ND	ND	ND	ND

TRY - Tryptamine

Analyzed Oct 30, 2025 | Instrument HPLC VWD | Method SOP-TRY

The expanded Uncertainty of the Tryptamine analysis is approximately $\pm 7.81\%$ at the 95% Confidence Level

Analyte	LOD ppm	LOQ ppm	Result %	Result mg/g	Result mg/Serving	Result mg/Unit
Norbaeocystin (NORB)	0.01	0.029	ND	ND	ND	ND
Baeocystin (BAEO)	0.01	0.029	ND	ND	ND	ND
Aeruginascin (AERU)	0.007	0.022	ND	ND	ND	ND
Norpsilocin (NORP)	0.003	0.009	ND	ND	ND	ND

PSY - Psilocybin & Psilocin

Analyzed Oct 30, 2025 | Instrument HPLC VWD | Method SOP-PSY

The expanded Uncertainty of the Psilocybin & Psilocin analysis is approximately $\pm 7.81\%$ at the 95% Confidence Level

Analyte	LOD ppm	LOQ ppm	Result %	Result mg/g	Result mg/Serving	Result mg/Unit
Psilocybin (PSCY)	0.007	0.019	ND	ND	ND	ND
Psilocin (PSCI)	0.003	0.009	ND	ND	ND	ND

UI Unidentified

ND Not Detected

N/A Not Applicable

NT Not Reported

LOD Limit of Detection

LOQ Limit of Quantification

<LOQ Detected

>ULOL Above upper limit of linearity

CFU/g Colony Forming Units per 1 gram

TNTC Too Numerous to Count



Coa_pjla_testing
(http://www.pjlabs.com)

Acc. #85368

DEA license: RP0611043

ISO/IEC 17025:2017 Acc.

85368

(https://www.dropbox.com/scl/fi/3qeqn2se34ulpw8lm13ui/85368.pdf?
rlkey=nviqubdnfk1v1f6rx32mew63u&st=8wa4rbwv&dl=0)



Scan the QR code to
verify.

Authorized Signature

Brandon_starr

Brandon Starr, Quality Assurance Manager

Tue, 04 Nov 2025 07:42:17 -0800



Pharmware_logo_simp
(https://pharmware.net)

PharmLabs San Diego | 3421 Hancock St, Second Floor, San Diego, CA 92110 | 619.356.0898 | ISO/IEC 17025:2017 Acc. 85368

PharmLabs hereby states that its Certificates of Analysis (COA) do not certify compliance with any federal, state, or local law or regulation, including but not limited to the 2018 Farm Bill. This COA is provided solely for informational purposes and is not intended for reliance by consumers or purchasers of a product. This report shall not be reproduced, except in full, without the prior written approval of PharmLabs. This report is not intended to diagnose, treat, cure, or prevent any disease. Results apply only to the specific sample(s) and batch(es) identified on this COA, and do not represent any other lot, batch, or product from this client. Measurement of uncertainty is available upon request and, when legally required, has been reported on the certificate. PharmLabs makes no representation or warranty, express or implied, regarding the tested product's safety, efficacy, quality, merchantability, or fitness for a particular purpose. PharmLabs expressly disclaims any liability for damages, claims, costs, or expenses arising out of the use, misuse, or reliance upon this COA by any party. PharmLabs relies on information provided by the client regarding the identity, sampling, and chain of custody of the submitted material. PharmLabs assumes no responsibility for errors, omissions, or misrepresentations in such information. It is the sole responsibility of the client to determine and ensure the compliance of their product(s) with all applicable federal, state, and local laws and regulations. This COA may not be used in whole or in part for marketing, advertising, promotional, or labeling purposes without the prior written consent of PharmLabs. This COA is valid only as of the date of issuance and does not guarantee the stability or continued conformity of the tested product beyond that date. Any dispute arising out of or related to this COA shall be governed by the laws of the State of California, without regard to its conflict of laws principles.

Sample MOLLY - G - VERY BERRY

Delta9 THC <LOQ	THCa ND	Total THC (THCa * 0.877 + THC) <LOQ	Delta8 THC ND
--------------------	------------	----------------------------------------	------------------



Sample ID SD251029-107 (126405)

Tested for MOLLY

Sampled - Received Oct 29, 2025

Matrix Edible

Reported Nov 04, 2025

Analyses executed CANX, 4AD, TRY, PSY

Unit Mass (g) 11.982

Num. of Servings 3

Serving Size (g) 3.99

CANx - Cannabinoids

Analyzed Oct 30, 2025 | Instrument HPLC-VWD | Method SOP-001

The expanded Uncertainty of the Cannabinoids analysis is approximately $\pm 7.81\%$ at the 95% Confidence Level

Analyte	LOD mg/g	LOQ mg/g	Result %	Result mg/g	Result mg/Serving	Result mg/Unit
11-Hydroxy- Δ -Tetrahydrocannabivarin (11-Hyd- Δ -8-THCV)	0.013	0.041	ND	ND	ND	ND
Cannabidiol (CBDO)	0.006	0.02	ND	ND	ND	ND
Abnormal Cannabidiol (a-CBDO)	0.013	0.038	ND	ND	ND	ND
(+/-)-9B-hydroxy-Hexahydrocannabinol (9b-HHC)	0.015	0.045	ND	ND	ND	ND
11-Hydroxy- Δ -Tetrahydrocannabinol (11-Hyd- Δ -8-THC)	0.015	0.045	ND	ND	ND	ND
Cannabidiolic Acid (CBDA)	0.033	0.16	ND	ND	ND	ND
Cannabigerol Acid (CBGA)	0.033	0.16	ND	ND	ND	ND
Cannabigerol (CBG)	0.048	0.16	ND	ND	ND	ND
Cannabidiol (CBD)	0.069	0.229	ND	ND	ND	ND
1(S)-Tetrahydrocannabinol (1(S)-H4-CBD)	0.008	0.026	ND	ND	ND	ND
1(R)-Tetrahydrocannabinol (1(R)-H4-CBD)	0.016	0.049	ND	ND	ND	ND
Tetrahydrocannabivarin (THCV)	0.049	0.162	ND	ND	ND	ND
Δ 8-tetrahydrocannabivarin (Δ 8-THCV)	0.012	0.036	ND	ND	ND	ND
Cannabidiolhexol (CBDH)	0.014	0.042	ND	ND	ND	ND
Tetrahydrocannabutol (Δ 9-THCB)	0.01	0.029	ND	ND	ND	ND
Cannabinol (CBN)	0.047	0.16	<LOQ	<LOQ	<LOQ	<LOQ
Cannabidiphorol (CBDP)	0.016	0.049	ND	ND	ND	ND
exo-THC (exo-THC)	0.016	0.8	ND	ND	ND	ND
Tetrahydrocannabinol (Δ 9-THC)	0.092	0.307	<LOQ	<LOQ	<LOQ	<LOQ
Δ 8-tetrahydrocannabinol (Δ 8-THC)	0.044	0.16	ND	ND	ND	ND
(6aR,9S)- Δ 10-Tetrahydrocannabinol ((6aR,9S)- Δ 10)	0.015	0.8	ND	ND	ND	ND
Hexahydrocannabinol (S Isomer) (9s-HHC)	0.017	0.8	ND	ND	ND	ND
(6aR,9R)- Δ 10-Tetrahydrocannabinol ((6aR,9R)- Δ 10)	0.007	0.8	ND	ND	ND	ND
Hexahydrocannabinol (R Isomer) (9r-HHC)	0.016	0.8	ND	ND	ND	ND
Tetrahydrocannabinolic Acid (THCA)	0.117	0.389	ND	ND	ND	ND
Δ 9-Tetrahydrocannabihexol (Δ 9-THCH)	0.02	0.061	ND	ND	ND	ND
Cannabinol Acetate (CBNO)	0.009	0.027	ND	ND	ND	ND
9(S)-Hexahydrocannabinolic Acid (9S)-HHCA)	0.063	0.065	ND	ND	ND	ND
9(R)-Hexahydrocannabinolic Acid (9R)-HHCA)	0.191	0.196	ND	ND	ND	ND
Δ 9-Tetrahydrocannabiphorol (Δ 9-THCP)	0.017	0.8	ND	ND	ND	ND
Δ 8-Tetrahydrocannabiphorol (Δ 8-THCP)	0.041	0.8	ND	ND	ND	ND
Cannabicitran (CBT)	0.005	0.16	ND	ND	ND	ND
Δ 8-THC-O-acetate (Δ 8-THCO)	0.076	0.8	ND	ND	ND	ND
9(S)-HHCP (s-HHCP)	0.013	0.041	ND	ND	ND	ND
Δ 9-THC-O-acetate (Δ 9-THCO)	0.066	0.8	ND	ND	ND	ND
9(R)-HHCP (r-HHCP)	0.015	0.045	ND	ND	ND	ND
9(S)-HHC-O-acetate (s-HHCO)	0.037	0.112	ND	ND	ND	ND
9(R)-HHC-O-acetate (r-HHCO)	0.031	0.093	ND	ND	ND	ND
3-octyl- Δ 8-Tetrahydrocannabinol (Δ 8-THC-C8)	0.021	0.062	ND	ND	ND	ND
Total THC (THCa * 0.877 + Δ 9THC)			ND	ND	ND	ND
Total THC + Δ 8THC + Δ 10THC (THCa * 0.877 + Δ 9THC + Δ 8THC + Δ 10THC)			ND	ND	ND	ND
Total CBD (CBDa * 0.877 + CBD)			ND	ND	ND	ND
Total CBG (CBGa * 0.877 + CBG)			ND	ND	ND	ND
Total HHC (9r-HHC + 9s-HHC)			ND	ND	ND	ND
Total Cannabinoids Analyzed			ND	ND	ND	ND

4AD - 4AD Tryptamines

Analyzed Oct 30, 2025 | Instrument HPLC VWD | Method SOP-4AD

The expanded Uncertainty of the 4AD Tryptamines analysis is approximately $\pm 7.81\%$ at the 95% Confidence Level

Analyte	LOD ppm	LOQ ppm	Result %	Result mg/g	Result mg/Serving	Result mg/Unit
Mescaline (MESC)	0.19	0.584	ND	ND	ND	ND
N-methyl Tryptamine (NMT)	0.004	0.013	ND	ND	ND	ND
4-Hydroxy-MET (4-HO-MET)	0.013	0.04	ND	ND	ND	ND
n,n Dimethyltryptamine (DMT)	0.015	0.048	ND	ND	ND	ND
Psilocetin (PSLA)	0.015	0.044	ND	ND	ND	ND
4-Hydroxy-DET (4-HO-DET)	0.014	0.042	ND	ND	ND	ND

4-Acetoxy-MET (4-AcO-MET)	0.018	0.053	ND	ND	ND	ND
4-Acetoxy-DET (4-AcO-DET)	0.004	0.011	ND	ND	ND	ND
4-Bromo-DMP (2C-B)	0.19	0.576	ND	ND	ND	ND

TRY - Tryptamine

Analyzed Oct 30, 2025 | Instrument HPLC VWD | Method SOP-TRY

The expanded Uncertainty of the Tryptamine analysis is approximately $\pm 7.81\%$ at the 95% Confidence Level

Analyte	LOD ppm	LOQ ppm	Result %	Result mg/g	Result mg/Serving	Result mg/Unit
Norbaeocystin (NORB)	0.01	0.029	ND	ND	ND	ND
Baeocystin (BAEO)	0.01	0.029	ND	ND	ND	ND
Aeruginascin (AERU)	0.007	0.022	ND	ND	ND	ND
Norpsilocin (NORP)	0.003	0.009	ND	ND	ND	ND

PSY - Psilocybin & Psilocin

Analyzed Oct 30, 2025 | Instrument HPLC VWD | Method SOP-PSY

The expanded Uncertainty of the Psilocybin & Psilocin analysis is approximately $\pm 7.81\%$ at the 95% Confidence Level

Analyte	LOD ppm	LOQ ppm	Result %	Result mg/g	Result mg/Serving	Result mg/Unit
Psilocybin (PSCY)	0.007	0.019	ND	ND	ND	ND
Psilocin (PSCI)	0.003	0.009	ND	ND	ND	ND

UI Unidentified

ND Not Detected

N/A Not Applicable

NT Not Reported

LOD Limit of Detection

LOQ Limit of Quantification

<LOQ Detected

>ULOL Above upper limit of linearity

CFU/g Colony Forming Units per 1 gram

TNTC Too Numerous to Count



Coa_pjla_testing
(http://www.pjlabs.com)

Acc. #85368

DEA license: RP0611043
ISO/IEC 17025:2017 Acc.
85368
(https://www.dropbox.com/scl/fi/3qeqn2se34ulpw8lm13ui/85368.pdf?
rlkey=nviqubdnfk1v1f6rx32mew63u&st=8wa4rbwv&dl=0)



Scan the QR code to
verify.

Authorized Signature



Brandon Starr

Brandon Starr, Quality Assurance Manager

Tue, 04 Nov 2025 07:42:03 -0800



Pharmware_logo_simp
(https://pharmware.net)

PharmLabs San Diego | 3421 Hancock St, Second Floor, San Diego, CA 92110 | 619.356.0898 | ISO/IEC 17025:2017 Acc. 85368

PharmLabs hereby states that its Certificates of Analysis (COA) do not certify compliance with any federal, state, or local law or regulation, including but not limited to the 2018 Farm Bill. This COA is provided solely for informational purposes and is not intended for reliance by consumers or purchasers of a product. This report shall not be reproduced, except in full, without the prior written approval of PharmLabs. This report is not intended to diagnose, treat, cure, or prevent any disease. Results apply only to the specific sample(s) and batch(es) identified on this COA, and do not represent any other lot, batch, or product from this client. Measurement of uncertainty is available upon request and, when legally required, has been reported on the certificate. PharmLabs makes no representation or warranty, express or implied, regarding the tested product's safety, efficacy, quality, merchantability, or fitness for a particular purpose. PharmLabs expressly disclaims any liability for damages, claims, costs, or expenses arising out of the use, misuse, or reliance upon this COA by any party. PharmLabs relies on information provided by the client regarding the identity, sampling, and chain of custody of the submitted material. PharmLabs assumes no responsibility for errors, omissions, or misrepresentations in such information. It is the sole responsibility of the client to determine and ensure the compliance of their product(s) with all applicable federal, state, and local laws and regulations. This COA may not be used in whole or in part for marketing, advertising, promotional, or labeling purposes without the prior written consent of PharmLabs. This COA is valid only as of the date of issuance and does not guarantee the stability or continued conformity of the tested product beyond that date. Any dispute arising out of or related to this COA shall be governed by the laws of the State of California, without regard to its conflict of laws principles.

Sample MOLLY - G - PURPLE PUNCH

Delta9 THC	ND	THCa	ND	Total THC (THCa * 0.877 + THC)	ND	Delta8 THC	<LOQ
------------	----	------	----	--------------------------------	----	------------	------



Sample ID SD251029-106 (126404)

Matrix Edible

Tested for MOLLY

Sampled - Received Oct 29, 2025

Reported Nov 04, 2025

Analyses executed CANX, 4AD, TRY, PSY

Unit Mass (g) 11.959

Num. of Servings 3

Serving Size (g) 3.99

CANx - Cannabinoids

Analyzed Oct 30, 2025 | Instrument HPLC-VWD | Method SOP-001

The expanded Uncertainty of the Cannabinoids analysis is approximately $\pm 7.81\%$ at the 95% Confidence Level

Analyte	LOD mg/g	LOQ mg/g	Result %	Result mg/g	Result mg/Serving	Result mg/Unit
11-Hydroxy- $\Delta 8$ -Tetrahydrocannabivarin (11-Hyd- $\Delta 8$ -THCV)	0.013	0.041	ND	ND	ND	ND
Cannabidiol (CBD)	0.006	0.02	ND	ND	ND	ND
Abnormal Cannabidiol (a-CBDO)	0.013	0.038	ND	ND	ND	ND
(+/-)-9B-hydroxy-Hexahydrocannabinol (9b-HHC)	0.015	0.045	ND	ND	ND	ND
11-Hydroxy- $\Delta 8$ -Tetrahydrocannabinol (11-Hyd- $\Delta 8$ -THC)	0.015	0.045	ND	ND	ND	ND
Cannabidiolic Acid (CBDA)	0.033	0.16	ND	ND	ND	ND
Cannabigerol Acid (CBGA)	0.033	0.16	ND	ND	ND	ND
Cannabigerol (CBG)	0.048	0.16	ND	ND	ND	ND
Cannabidiol (CBD)	0.069	0.229	<LOQ	<LOQ	<LOQ	<LOQ
1(S)-Tetrahydrocannabidiol (1(S)-H4-CBD)	0.008	0.026	ND	ND	ND	ND
1(R)-Tetrahydrocannabidiol (1(R)-H4-CBD)	0.016	0.049	ND	ND	ND	ND
Tetrahydrocannabivarin (THCV)	0.049	0.162	ND	ND	ND	ND
$\Delta 8$ -tetrahydrocannabivarin ($\Delta 8$ -THCV)	0.012	0.036	ND	ND	ND	ND
Cannabidiolhexol (CBDH)	0.014	0.042	ND	ND	ND	ND
Tetrahydrocannabutol ($\Delta 9$ -THCB)	0.01	0.029	ND	ND	ND	ND
Cannabinol (CBN)	0.047	0.16	<LOQ	<LOQ	<LOQ	<LOQ
Cannabidiphorol (CBDP)	0.016	0.049	ND	ND	ND	ND
exo-THC (exo-THC)	0.016	0.8	ND	ND	ND	ND
Tetrahydrocannabinol ($\Delta 9$ -THC)	0.092	0.307	ND	ND	ND	ND
$\Delta 8$ -tetrahydrocannabinol ($\Delta 8$ -THC)	0.044	0.16	<LOQ	<LOQ	<LOQ	<LOQ
(6aR,9S)- $\Delta 10$ -Tetrahydrocannabinol ((6aR,9S)- $\Delta 10$)	0.015	0.8	ND	ND	ND	ND
Hexahydrocannabinol (S Isomer) (9s-HHC)	0.017	0.8	ND	ND	ND	ND
(6aR,9R)- $\Delta 10$ -Tetrahydrocannabinol ((6aR,9R)- $\Delta 10$)	0.007	0.8	ND	ND	ND	ND
Hexahydrocannabinol (R Isomer) (9r-HHC)	0.016	0.8	ND	ND	ND	ND
Tetrahydrocannabinolic Acid (THCA)	0.117	0.389	ND	ND	ND	ND
$\Delta 9$ -Tetrahydrocannabihexol ($\Delta 9$ -THCH)	0.02	0.061	ND	ND	ND	ND
Cannabinol Acetate (CBNO)	0.009	0.027	ND	ND	ND	ND
9(S)-Hexahydrocannabinolic Acid (9(S)-HHCA)	0.063	0.065	ND	ND	ND	ND
9(R)-Hexahydrocannabinolic Acid (9(R)-HHCA)	0.191	0.196	ND	ND	ND	ND
$\Delta 9$ -Tetrahydrocannabiphorol ($\Delta 9$ -THCP)	0.017	0.8	ND	ND	ND	ND
$\Delta 8$ -Tetrahydrocannabiphorol ($\Delta 8$ -THCP)	0.041	0.8	ND	ND	ND	ND
Cannabicitran (CBT)	0.005	0.16	ND	ND	ND	ND
$\Delta 8$ -THC-O-acetate ($\Delta 8$ -THCO)	0.076	0.8	ND	ND	ND	ND
9(S)-HHCP (s-HHCP)	0.013	0.041	ND	ND	ND	ND
$\Delta 9$ -THC-O-acetate ($\Delta 9$ -THCO)	0.066	0.8	ND	ND	ND	ND
9(R)-HHCP (r-HHCP)	0.015	0.045	ND	ND	ND	ND
9(S)-HHC-O-acetate (s-HHCO)	0.037	0.112	ND	ND	ND	ND
9(R)-HHC-O-acetate (r-HHCO)	0.031	0.093	ND	ND	ND	ND
3-octyl- $\Delta 8$ -Tetrahydrocannabinol ($\Delta 8$ -THC-C8)	0.021	0.062	ND	ND	ND	ND
Total THC (THCa * 0.877 + $\Delta 9$ THC)			ND	ND	ND	ND
Total THC + $\Delta 8$ THC + $\Delta 10$ THC (THCa * 0.877 + $\Delta 9$ THC + $\Delta 8$ THC + $\Delta 10$ THC)			ND	ND	ND	ND
Total CBD (CBDA * 0.877 + CBD)			ND	ND	ND	ND
Total CBG (CBGA * 0.877 + CBG)			ND	ND	ND	ND
Total HHC (9r-HHC + 9s-HHC)			ND	ND	ND	ND
Total Cannabinoids Analyzed			ND	ND	ND	ND

4AD - 4AD Tryptamines

Analyzed Oct 30, 2025 | Instrument HPLC VWD | Method SOP-4AD

The expanded Uncertainty of the 4AD Tryptamines analysis is approximately $\pm 7.81\%$ at the 95% Confidence Level

Analyte	LOD ppm	LOQ ppm	Result %	Result mg/g	Result mg/Serving	Result mg/Unit
Mescaline (MESC)	0.19	0.584	ND	ND	ND	ND
N-methyl Tryptamine (NMT)	0.004	0.013	ND	ND	ND	ND
4-Hydroxy-MET (4-HO-MET)	0.013	0.04	ND	ND	ND	ND
n,n Dimethyltryptamine (DMT)	0.015	0.048	ND	ND	ND	ND
Psilocetin (PSLA)	0.015	0.044	ND	ND	ND	ND
4-Hydroxy-DET (4-HO-DET)	0.014	0.042	ND	ND	ND	ND

4-Acetoxy-MET (4-AcO-MET)	0.018	0.053	ND	ND	ND	ND
4-Acetoxy-DET (4-AcO-DET)	0.004	0.011	ND	ND	ND	ND
4-Bromo-DMP (2C-B)	0.19	0.576	ND	ND	ND	ND

TRY - Tryptamine

Analyzed Oct 30, 2025 | Instrument HPLC VWD | Method SOP-TRY

The expanded Uncertainty of the Tryptamine analysis is approximately $\pm 7.81\%$ at the 95% Confidence Level

Analyte	LOD ppm	LOQ ppm	Result %	Result mg/g	Result mg/Serving	Result mg/Unit
Norbaeocystin (NORB)	0.01	0.029	ND	ND	ND	ND
Baeocystin (BAEO)	0.01	0.029	ND	ND	ND	ND
Aeruginascin (AERU)	0.007	0.022	ND	ND	ND	ND
Norpsilocin (NORP)	0.003	0.009	ND	ND	ND	ND

PSY - Psilocybin & Psilocin

Analyzed Oct 30, 2025 | Instrument HPLC VWD | Method SOP-PSY

The expanded Uncertainty of the Psilocybin & Psilocin analysis is approximately $\pm 7.81\%$ at the 95% Confidence Level

Analyte	LOD ppm	LOQ ppm	Result %	Result mg/g	Result mg/Serving	Result mg/Unit
Psilocybin (PSCY)	0.007	0.019	ND	ND	ND	ND
Psilocin (PSCI)	0.003	0.009	ND	ND	ND	ND

UI Unidentified

ND Not Detected

N/A Not Applicable

NT Not Reported

LOD Limit of Detection

LOQ Limit of Quantification

<LOQ Detected

>ULOL Above upper limit of linearity

CFU/g Colony Forming Units per 1 gram

TNTC Too Numerous to Count



Coa_pjla_testing
(http://www.pjlabs.com)

Acc. #85368

DEA license: RP0611043

ISO/IEC 17025:2017 Acc.

85368

(https://www.dropbox.com/scl/fi/3qeqn2se34ulpw8lm13ui/85368.pdf?
rlkey=nviqubdnfk1v1f6rx32mew63u&st=8wa4rbwv&dl=0)



Scan the QR code to
verify.

Authorized Signature

Brandon_starr

Brandon Starr, Quality Assurance Manager

Tue, 04 Nov 2025 07:42:01 -0800



Pharmware_logo_simp
(https://pharmware.net)

PharmLabs San Diego | 3421 Hancock St, Second Floor, San Diego, CA 92110 | 619.356.0898 | ISO/IEC 17025:2017 Acc. 85368

PharmLabs hereby states that its Certificates of Analysis (COA) do not certify compliance with any federal, state, or local law or regulation, including but not limited to the 2018 Farm Bill. This COA is provided solely for informational purposes and is not intended for reliance by consumers or purchasers of a product. This report shall not be reproduced, except in full, without the prior written approval of PharmLabs. This report is not intended to diagnose, treat, cure, or prevent any disease. Results apply only to the specific sample(s) and batch(es) identified on this COA and do not represent any other lot, batch, or product from this client. Measurement of uncertainty is available upon request and, when legally required, has been reported on the certificate. PharmLabs makes no representation or warranty, express or implied, regarding the tested product's safety, efficacy, quality, merchantability, or fitness for a particular purpose. PharmLabs expressly disclaims any liability for damages, claims, costs, or expenses arising out of the use, misuse, or reliance upon this COA by any party. PharmLabs relies on information provided by the client regarding the identity, sampling, and chain of custody of the submitted material. PharmLabs assumes no responsibility for errors, omissions, or misrepresentations in such information. It is the sole responsibility of the client to determine and ensure the compliance of their product(s) with all applicable federal, state, and local laws and regulations. This COA may not be used in whole or in part for marketing, advertising, promotional, or labeling purposes without the prior written consent of PharmLabs. This COA is valid only as of the date of issuance and does not guarantee the stability or continued conformity of the tested product beyond that date. Any dispute arising out of or related to this COA shall be governed by the laws of the State of California, without regard to its conflict of laws principles.

Sample MOLLY - G - GUAVA

Delta9 THC ND	THCa <LOQ	Total THC (THCa * 0.877 + THC) <LOQ	Delta8 THC <LOQ
------------------	--------------	----------------------------------------	--------------------



Sample ID SD251029-105 (126403)

Tested for MOLLY

Sampled - Received Oct 29, 2025

Matrix Edible

Analyses executed CANX, 4AD, TRY, PSY

Reported Nov 04, 2025

Unit Mass (g) 11.983

Num. of Servings 3

Serving Size (g) 3.99

CANx - Cannabinoids

Analyzed Oct 30, 2025 | Instrument HPLC-VWD | Method SOP-001

The expanded Uncertainty of the Cannabinoids analysis is approximately $\pm 7.81\%$ at the 95% Confidence Level

Analyte	LOD mg/g	LOQ mg/g	Result %	Result mg/g	Result mg/Serving	Result mg/Unit
11-Hydroxy- Δ -Tetrahydrocannabivarin (11-Hyd- Δ -8-THCV)	0.013	0.041	ND	ND	ND	ND
Cannabidiol (CBDO)	0.006	0.02	ND	ND	ND	ND
Abnormal Cannabidiol (a-CBDO)	0.013	0.038	ND	ND	ND	ND
(+/-)-9B-hydroxy-Hexahydrocannabinol (9b-HHC)	0.015	0.045	ND	ND	ND	ND
11-Hydroxy- Δ -Tetrahydrocannabinol (11-Hyd- Δ -8-THC)	0.015	0.045	ND	ND	ND	ND
Cannabidiolic Acid (CBDA)	0.033	0.16	ND	ND	ND	ND
Cannabigerol Acid (CBGA)	0.033	0.16	ND	ND	ND	ND
Cannabigerol (CBG)	0.048	0.16	ND	ND	ND	ND
Cannabidiol (CBD)	0.069	0.229	<LOQ	<LOQ	<LOQ	<LOQ
(1S)-Tetrahydrocannabinol (1(S)-H4-CBD)	0.008	0.026	ND	ND	ND	ND
(1R)-Tetrahydrocannabinol (1(R)-H4-CBD)	0.016	0.049	ND	ND	ND	ND
Tetrahydrocannabivarin (THCV)	0.049	0.162	ND	ND	ND	ND
Δ 8-tetrahydrocannabivarin (Δ 8-THCV)	0.012	0.036	ND	ND	ND	ND
Cannabidiolhexol (CBDH)	0.014	0.042	ND	ND	ND	ND
Tetrahydrocannabutol (Δ 9-THCB)	0.01	0.029	ND	ND	ND	ND
Cannabinol (CBN)	0.047	0.16	<LOQ	<LOQ	<LOQ	<LOQ
Cannabidiphorol (CBDP)	0.016	0.049	ND	ND	ND	ND
exo-THC (exo-THC)	0.016	0.8	ND	ND	ND	ND
Tetrahydrocannabinol (Δ 9-THC)	0.092	0.307	ND	ND	ND	ND
Δ 8-tetrahydrocannabinol (Δ 8-THC)	0.044	0.16	<LOQ	<LOQ	<LOQ	<LOQ
(6aR,9S)- Δ 10-Tetrahydrocannabinol ((6aR,9S)- Δ 10)	0.015	0.8	ND	ND	ND	ND
Hexahydrocannabinol (S Isomer) (9s-HHC)	0.017	0.8	ND	ND	ND	ND
(6aR,9R)- Δ 10-Tetrahydrocannabinol ((6aR,9R)- Δ 10)	0.007	0.8	ND	ND	ND	ND
Hexahydrocannabinol (R Isomer) (9r-HHC)	0.016	0.8	ND	ND	ND	ND
Tetrahydrocannabinolic Acid (THCA)	0.117	0.389	<LOQ	<LOQ	<LOQ	<LOQ
Δ 9-Tetrahydrocannabihexol (Δ 9-THCH)	0.02	0.061	ND	ND	ND	ND
Cannabinol Acetate (CBNO)	0.009	0.027	ND	ND	ND	ND
9(S)-Hexahydrocannabinolic Acid (9S)-HHCA)	0.063	0.065	ND	ND	ND	ND
9(R)-Hexahydrocannabinolic Acid (9R)-HHCA)	0.191	0.196	ND	ND	ND	ND
Δ 9-Tetrahydrocannabiphorol (Δ 9-THCP)	0.017	0.8	ND	ND	ND	ND
Δ 8-Tetrahydrocannabiphorol (Δ 8-THCP)	0.041	0.8	ND	ND	ND	ND
Cannabicitran (CBT)	0.005	0.16	ND	ND	ND	ND
Δ 8-THC-O-acetate (Δ 8-THCO)	0.076	0.8	ND	ND	ND	ND
9(S)-HHCP (s-HHCP)	0.013	0.041	ND	ND	ND	ND
Δ 9-THC-O-acetate (Δ 9-THCO)	0.066	0.8	ND	ND	ND	ND
9(R)-HHCP (r-HHCP)	0.015	0.045	ND	ND	ND	ND
9(S)-HHC-O-acetate (s-HHCO)	0.037	0.112	ND	ND	ND	ND
9(R)-HHC-O-acetate (r-HHCO)	0.031	0.093	ND	ND	ND	ND
3-octyl- Δ 8-Tetrahydrocannabinol (Δ 8-THC-C8)	0.021	0.062	ND	ND	ND	ND
Total THC (THCa * 0.877 + Δ 9THC)			ND	ND	ND	ND
Total THC + Δ 8THC + Δ 10THC (THCa * 0.877 + Δ 9THC + Δ 8THC + Δ 10THC)			ND	ND	ND	ND
Total CBD (CBDA * 0.877 + CBD)			ND	ND	ND	ND
Total CBG (CBGa * 0.877 + CBG)			ND	ND	ND	ND
Total HHC (9r-HHC + 9s-HHC)			ND	ND	ND	ND
Total Cannabinoids Analyzed			ND	ND	ND	ND

4AD - 4AD Tryptamines

Analyzed Oct 30, 2025 | Instrument HPLC VWD | Method SOP-4AD

The expanded Uncertainty of the 4AD Tryptamines analysis is approximately $\pm 7.81\%$ at the 95% Confidence Level

Analyte	LOD ppm	LOQ ppm	Result %	Result mg/g	Result mg/Serving	Result mg/Unit
Mescaline (MESC)	0.19	0.584	ND	ND	ND	ND
N-methyl Tryptamine (NMT)	0.004	0.013	ND	ND	ND	ND
4-Hydroxy-MET (4-HO-MET)	0.013	0.04	ND	ND	ND	ND
n,n Dimethyltryptamine (DMT)	0.015	0.048	ND	ND	ND	ND
Psilocetin (PSLA)	0.015	0.044	ND	ND	ND	ND
4-Hydroxy-DET (4-HO-DET)	0.014	0.042	ND	ND	ND	ND

4-Acetoxy-MET (4-AcO-MET)	0.018	0.053	ND	ND	ND	ND
4-Acetoxy-DET (4-AcO-DET)	0.004	0.011	ND	ND	ND	ND
4-Bromo-DMP (2C-B)	0.19	0.576	ND	ND	ND	ND

TRY - Tryptamine

Analyzed Oct 30, 2025 | Instrument HPLC VWD | Method SOP-TRY

The expanded Uncertainty of the Tryptamine analysis is approximately $\pm 7.81\%$ at the 95% Confidence Level

Analyte	LOD ppm	LOQ ppm	Result %	Result mg/g	Result mg/Serving	Result mg/Unit
Norbaeocystin (NORB)	0.01	0.029	ND	ND	ND	ND
Baeocystin (BAEO)	0.01	0.029	ND	ND	ND	ND
Aeruginascin (AERU)	0.007	0.022	ND	ND	ND	ND
Norpsilocin (NORP)	0.003	0.009	ND	ND	ND	ND

PSY - Psilocybin & Psilocin

Analyzed Oct 30, 2025 | Instrument HPLC VWD | Method SOP-PSY

The expanded Uncertainty of the Psilocybin & Psilocin analysis is approximately $\pm 7.81\%$ at the 95% Confidence Level

Analyte	LOD ppm	LOQ ppm	Result %	Result mg/g	Result mg/Serving	Result mg/Unit
Psilocybin (PSCY)	0.007	0.019	ND	ND	ND	ND
Psilocin (PSCI)	0.003	0.009	ND	ND	ND	ND

UI Unidentified

ND Not Detected

N/A Not Applicable

NT Not Reported

LOD Limit of Detection

LOQ Limit of Quantification

<LOQ Detected

>ULOL Above upper limit of linearity

CFU/g Colony Forming Units per 1 gram

TNTC Too Numerous to Count



Coa_pjla_testing
(http://www.pjlabs.com)

Acc. #85368

DEA license: RP0611043

ISO/IEC 17025:2017 Acc.

85368

(https://www.dropbox.com/scl/fi/3qeqn2se34ulpw8lm13ui/85368.pdf?
rlkey=nviqubdnfk1v1f6rx32mew63u&st=8wa4rbwv&dl=0)



Scan the QR code to
verify.

Authorized Signature



Brandon_starr

Brandon Starr, Quality Assurance Manager

Tue, 04 Nov 2025 07:42:00 -0800



Pharmware_logo_simp
(https://pharmware.net)

PharmLabs San Diego | 3421 Hancock St, Second Floor, San Diego, CA 92110 | 619.356.0898 | ISO/IEC 17025:2017 Acc. 85368

PharmLabs hereby states that its Certificates of Analysis (COA) do not certify compliance with any federal, state, or local law or regulation, including but not limited to the 2018 Farm Bill. This COA is provided solely for informational purposes and is not intended for reliance by consumers or purchasers of a product. This report shall not be reproduced, except in full, without the prior written approval of PharmLabs. This report is not intended to diagnose, treat, cure, or prevent any disease. Results apply only to the specific sample(s) and batch(es) identified on this COA, and do not represent any other lot, batch, or product from this client. Measurement of uncertainty is available upon request and, when legally required, has been reported on the certificate. PharmLabs makes no representation or warranty, express or implied, regarding the tested product's safety, efficacy, quality, merchantability, or fitness for a particular purpose. PharmLabs expressly disclaims any liability for damages, claims, costs, or expenses arising out of the use, misuse, or reliance upon this COA by any party. PharmLabs relies on information provided by the client regarding the identity, sampling, and chain of custody of the submitted material. PharmLabs assumes no responsibility for errors, omissions, or misrepresentations in such information. It is the sole responsibility of the client to determine and ensure the compliance of their product(s) with all applicable federal, state, and local laws and regulations. This COA may not be used in whole or in part for marketing, advertising, promotional, or labeling purposes without the prior written consent of PharmLabs. This COA is valid only as of the date of issuance and does not guarantee the stability or continued conformity of the tested product beyond that date. Any dispute arising out of or related to this COA shall be governed by the laws of the State of California, without regard to its conflict of laws principles.